Efficient and reliable scale-up is one of the major hurdles in modern biotechnology. Engineering parameters such as impeller tip speed, oxygen transfer rate, impeller power number (Np) and the impeller power consumption per volume (P/V) are just a few of the parameters that need to be considered to ensure a successful tech transfer from bench to pilot and production scale. The BioFlo® 720 bioreactor control system was designed to save time and to mitigate risks.
BioFlo® 720: Experience Seamless Scalability of Your Bioprocess
ProductsEfficient and reliable scale-up is one of the major hurdles in modern biotechnology. Engineering parameters such as impeller tip speed, oxygen transfer rate, impeller power number (Np) and the impeller power consumption per volume (P/V) are just a few of the parameters that need to be considered to ensure a successful tech transfer from bench to pilot and production scale. The BioFlo® 720 bioreactor control system was designed to save time and to mitigate risks.
Abcam to acquire BioVision for $340m
Latest NewsLife sciences tool provider Abcam plc has entered into a definitive agreement to acquire BioVision, Inc. for $340m.
Vaccine development – strategic approach
Sponsored PublicationsThis white paper explores vaccine development during a pandemic, a response to complex challenges that traditional manufacturing methods won’t solve.
Byondis and Glycotope merge platforms to target carbohydrates
Latest NewsCancer and autoimmunity specialist Byondis BV and carbohydrate-targeting antibody company Glycotope have entered into a platform access agreement.
Artios Pharma Ltd raises US-$153m Series C financing
Latest NewsCancer specialist Artios Pharma has raised $153m in a Series C Financing led by Omega Funds and TCG X to progress its clinical pipeline.
AXA IM Alts raises €1.9bn European Life Sciences Fund
Latest NewsAXA IM Alts has raised €1.9bn of equity to accelerate investments into the Life Sciences sector.
New head for Orbit Discovery
AppointmentsDr Neil Butt is the new Chief Executive Officer at Oxford-based Orbit Discovery.
Synaffix inks $246m deal with ProfoundBio
Latest NewsSynaffix has nonexclusivey licensed its award-winning ADC technologies to Chinese ProfoundBio in an up to $246m deal
Panakès expands into biotech with €150m fund
Latest NewsItalian venture capital firm Panakès Partners, previously active in medtech, has closed the €150m purple fund with the goal to invest in underserved European Life Science companies.
BioNTech takes over cancer immunotherapy platform
Latest NewsMainz-based BioNTech is expanding its portfolio for cancer therapies with the neoantigen TCR Cell Therapy R&D pipeline and manufacturing site from Gilead Science subsidiary Kite Pharmaceuticals.